- Home
- ADNT vs OCUL Comparison
ADNT vs OCUL Comparison
Compare ADNT & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADNT | OCUL |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ADNT | OCUL |
|---|---|---|
| Price | $20.12 | $8.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $24.85 | $22.90 |
| AVG Volume (30 Days) | 657.8K | ★ 7.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,439,000,000.00 | $1,990,000.00 |
| Revenue This Year | $2.76 | $9.35 |
| Revenue Next Year | $2.47 | $92.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.56 | 3.48 |
| 52 Week Low | $10.04 | $6.23 |
| 52 Week High | $27.32 | $16.44 |
Technical Indicators
Market Signals| Indicator | ADNT | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 44.02 |
| Support Level | $18.47 | $8.36 |
| Resistance Level | $23.87 | $12.49 |
| Average True Range (ATR) | 0.76 | 0.68 |
| MACD | -0.43 | -0.08 |
| Stochastic Oscillator | 11.19 | 12.66 |
Price Performance
Historical ComparisonAbout ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.